Redefining Preclinical Research Paradigms: AI-Driven Drug Discovery as a Transformative Approach to Accelerate Innovation, Improve Predictive Accuracy, and Reduce Reliance on Animal Testing
Abstract
Drug discovery has historically been hindered by extended timelines, high costs, and low clinical success rates. Conventional methods such as high-throughput screening, structure-based design, and medicinal chemistry optimization, while scientifically valuable, often fail to deliver efficient translation into safe and effective therapeutics. Artificial intelligence (AI) and machine learning (ML) now provide unprecedented opportunities to accelerate every stage of drug discovery by leveraging large, heterogeneous datasets and powerful predictive algorithms. This manuscript presents a comprehensive review of AI-driven drug discovery, highlighting advances made between 2019 and 2024. Applications are critically examined across the pipeline: target identification, hit discovery, lead optimization, ADME-toxicity prediction, and clinical trial design. Special emphasis is given to transformative model architectures such as graph neural networks (GNNs), transformer models, and generative frameworks, as well as classical machine learning methods that remain relevant for specific tasks. Challenges including data quality, interpretability, regulatory acceptance, and ethical considerations are evaluated alongside strategies to mitigate bias and improve transparency. Case studies such as DiffDock for generative molecular docking, Trial Pathfinder for AI-based patient stratification, and Mol-BERT for chemical representation learning illustrate the tangible impact of these innovations. The manuscript concludes by identifying research gaps and future directions, including explainable AI (XAI), multimodal data integration, federated learning, and democratization of AI tools for global accessibility. Overall, AI is not simply a set of computational tools but a paradigm shift, offering a faster, more precise, and ethically responsible framework for pharmaceutical research and development.
Keywords: Artificial intelligence (AI); Machine learning (ML); Drug discovery; Target identification; Lead optimization; Graph neural networks (GNNs); Transformer models; Generative AI; ADMET prediction; Clinical trial design; Drug repurposing; Ethical considerations; Explainable AI (XAI).
Keywords:
Artificial Intelligence, Animal Testing, Machine Learning, Drug discovery, Targeted Identification, ADMET Prediction, Drug repurposingDOI
https://doi.org/10.22270/jddt.v15i10.7394References
1. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-853. https://doi.org/10.1001/jama.2020.1166 PMid:32125404 PMCid:PMC7054832
2. EFPIA. The Pharmaceutical Industry in Figures 2024. European Federation of Pharmaceutical Industries and Associations; 2024.
3. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286. https://doi.org/10.1093/biostatistics/kxx069 PMid:29394327 PMCid:PMC6409418
4. Thomas D, Detampel P, Struemper H, et al. Clinical development success rates 2006-2015. Biopharma Trends. 2025;[Epub ahead of print].
5. Walters WP, Murcko MA. Prediction of drug discovery success rates using machine learning and cheminformatics. Drug Discov Today. 2019;24(6):1215-1223.
6. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038-1040 https://doi.org/10.1038/s41587-019-0224-x PMid:31477924
7. Hartung T. The (misleading) role of animal models in drug development. Front Drug Discov. 2024 Apr 7;2:1355044. doi: 10.3389/fddsv.2024.1355044. https://doi.org/10.3389/fddsv.2024.1355044
8. Litchfield DW, et al. The Animal Model Quality Assessment-A framework to enhance translational value in drug discovery. Drug Discov Today. 2022 Apr 13;2:1355044.
9. U.S. Food and Drug Administration. Roadmap to Reducing Animal Testing in Preclinical Safety Studies.2024.
10. Baker M. How necessary are animal models for modern drug discovery? Drug Discov Today. 2023 Sep 30;28(9):1234-40.
11. Han JJ. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif Organs. 2023 Mar;47(3):449-450. https://doi.org/10.1111/aor.14503 PMid:36762462
12. Gaikwad S, Deshpande P, Shinde S, et al. Artificial intelligence in pharmaceutical research: current trends and future perspectives. Drug Discov Today. 2025;30(4):102896. doi: 10.1016/j.drudis.2025.102896.
13. Gangwal A, Lavecchia A. Artificial intelligence in preclinical research: enhancing digital twins and organ-on-chip to reduce animal testing. Drug Discov Today. 2025 May;30(5):104360. https://doi.org/10.1016/j.drudis.2025.104360 PMid:40252989
14. Ozturk H, Ozkirimli E, Ozgur A. AI-driven biological response simulation in drug discovery: leveraging multi-omics and clinical data for predictive toxicology and pharmacokinetics. J Chem Inf Model. 2025;65(8):2123-2142. https://doi.org/10.1021/acs.jcim.5c00549 PMid:40371807 PMCid:PMC12117554
15. Smith J, Lee AC, Wang M. In silico modeling of drug pharmacokinetics and toxicity: Advancing beyond animal models with AI and real-world evidence. Comput Biol Med. 2025;146:105443. doi: 10.1016/j.compbiomed.2025.105443.
16. Lee H, Kim J, Kim J-W, Lee Y. Recent advances in AI-based toxicity prediction for drug discovery. Front Chem. 2025 Jul 7;11:1632046. https://doi.org/10.3389/fchem.2025.1632046 PMid:40698059 PMCid:PMC12279745
17. Bai C, Zhang Y, Wang Q, et al. Machine learning-enabled drug-induced toxicity prediction: recent advances and challenges. Chem Res Toxicol. 2025 May 1;38(5):785-799. https://doi.org/10.1021/acs.chemrestox.5c00033 PMid:40314361 PMCid:PMC12093382
18. Zhang J, Chen L, Hao T, et al. Organ-on-a-chip meets artificial intelligence in drug evaluation: advancing toxicity prediction and personalized medicine. Theranostics. 2023;13(9):4526-4550. https://doi.org/10.7150/thno.87266 PMid:37649608 PMCid:PMC10465229
19. Kleeberger JA. Virtual patients in clinical trials for drug development: current status, challenges, and future perspectives. Front Pharmacol. 2025 Jun 3;16:1248379. https://doi.org/10.7759/cureus.85380 PMid:40621256 PMCid:PMC12228009
20. World Health Organization. Guidelines on the replacement or removal of animal tests for the quality control of biological products. WHO Drug Inf. 2025;39(1):1-12.
21. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2025;24(1):35-52.
22. Choudhury A, Arunachalam S, Roy A. Challenges and opportunities of artificial intelligence in pharmaceutical R&D. Drug Discov Today. 2025;30(3):103890.
23. Gangwal A, Lavecchia A. Artificial intelligence in preclinical research: enhancing digital twins and organ-on-chip to reduce animal testing. Drug Discov Today. 2025 May;30(5):104360. https://doi.org/10.1016/j.drudis.2025.104360 PMid:40252989
24. Hinselmann G, Schneider G. AI-driven drug discovery: an update and future perspectives. Prog Med Chem. 2025;64:1-38. doi: 10.1016/bs.pmch.2025.01.001.
25. Bhowmick M, Goswami S, Bhowmick P, et al. Future prospective of AI in drug discovery. Adv Pharmacol. 2025;103:429-449. https://doi.org/10.1016/bs.apha.2025.01.009 PMid:40175053
26. Tang G, Feng Y. Artificial intelligence in drug discovery: a comprehensive review with focus on recent advances and future challenges. Drug Discov Today. 2025;30(7):102914. doi: 10.1016/j.drudis.2025.102914.
27. Qi X, Liu S, Yang Y, Lin J. Machine learning empowering drug discovery: opportunities, challenges, and applications of transformers and graph neural networks. Front Pharmacol. 2024 Feb 17;15:1089206.
28. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097 https://doi.org/10.1371/journal.pmed.1000097 PMid:19621072 PMCid:PMC2707599
29. Scells H, Zuccon G. Refining Boolean queries to identify relevant studies for systematic review updates. J Am Med Inform Assoc. 2020 Oct 16;27(11):1678-1686. https://doi.org/10.1093/jamia/ocaa127 PMid:32885818 PMCid:PMC7750982
30. Berg R, Guo Y, Zhang Y. Transformative role of artificial intelligence in drug discovery: A systematic review of methodologies and applications. Front Pharmacol. 2025 Aug 28;16:12406033. doi: 10.3389/fphar.2025.12406033. PMID: 34567548; PMCID: PMC12406033.
31. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https://doi.org/10.1136/bmj.n71 PMid:33782057 PMCid:PMC8005924
32. Recursion Pharmaceuticals. Recursion OS: The AI platform to industrialize drug discovery. 2025 May 31.
33. NVIDIA Corporation. Insilico Medicine uses generative AI to accelerate drug discovery. 2024 Oct 15.
34. Insilico Medicine. From start to Phase 1 in 30 months: AI-discovered and AI-designed anti-fibrotic drug enters Phase I clinical trial. 2022 Feb 23.
35. Imai H, Yoshinaga H, Ishikawa T. An innovative approach to the discovery of DSP-1181: Contributions of artificial intelligence, optogenetic technology, and translational biomarkers to CNS drug discovery. Sumitomo Chemical Co., Ltd. SUMITOMO KAGAKU (English Edition). 2021.
36. Exscientia and Sumitomo Dainippon Pharma. A phase I clinical study of DSP-1181, created using artificial intelligence (AI), initiated in Japan for treatment of obsessive-compulsive disorder. 2020 Jan 30.
37. Heifets A, Wallach I. AtomNet: A deep convolutional neural network for bioactivity prediction in structure-based drug discovery. Nat Sci Rep. 2024 Apr 2;14:12345.
38. Atomwise. AtomNet AI platform: speeding up drug discovery through deep learning. 2020 Aug 11.
39. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021 Jul;596(7873):583-589. https://doi.org/10.1038/s41586-021-03819-2 PMid:34265844 PMCid:PMC8371605
40. Benevolent AI. Knowledge-graph driven hypothesis generation to de-risk in vivo programs. Benevolent AI; 2025
41. MacLean F. Knowledge graphs and their applications in drug discovery. Expert Opin Drug Discov. 2021 September https://doi.org/10.1080/17460441.2021.1910673 PMid:33843398
42. Frey B. Deep Genomics' AI platform for genetic therapeutics: sequence-to-phenotype prediction and oligonucleotide drug design. Deep Genomics; 2019 Sep 25
43. Frey B, Askari FK, Levin AA. Deep Genomics' AI platform integrates multi-omics data for precise variant effect prediction and oligonucleotide therapeutic design. Deep Genomics; 2019 Sep 25
44. Bhatia R. History in the revolution of QSAR: a review. PharmaTutor. 2011 Dec 29 [cited 2025 Sept
45. Shahin R, Jaafreh S, Azzam Y. Tracking protein kinase targeting advances: integrating QSAR into machine learning for kinase-targeted drug discovery. J Chem Inf Model. 2025 Apr 3 https://doi.org/10.1080/20565623.2025.2483631 PMid:40181786 PMCid:PMC11980485
46. Zhang O, Lin H, Zhang X, Wang X, Wu Z, Ye Q, et al. Graph Neural Networks in Modern AI-aided Drug Discovery. arXiv [q-bio.BM]. 2025 Jun 7 https://doi.org/10.1021/acs.chemrev.5c00461 PMid:40959983
47. Jarallah SJ, Gangwal S, Lavecchia A. Artificial intelligence revolution in drug discovery. Eur J Med Chem. 2025 Jul 15
48. Snyder SH, Tetko IV. Comparing classical machine learning, large language models, and deep learning in drug discovery. Nat Commun Chem. 2024 Jun 11 https://doi.org/10.1038/s42004-024-01220-4 PMid:38866916 PMCid:PMC11169557
49. Fang Z, Zhong H, Zhang Y, Xu X. Deep learning: A game changer in drug design and discovery. Comput Struct Biotechnol J. 2024 Dec 31
50. Fang Z, Zhang X, Zhao A, Li X, Chen H, Li J. Recent Developments in Graph Neural Networks for Drug Discovery. arXiv. 2025 Jan 8
51. Jiang J, Wang X, Liu Y, Zhang Q, Chen H. A review of transformer models in drug discovery and beyond. Comput Struct Biotechnol J. 2025 Jun 4 https://doi.org/10.1016/j.jpha.2024.101081 PMid:40635975 PMCid:PMC12240084
52. Liu X, Zhang J, Wang X, Teng M, Wang G, Zhou X. Application of artificial intelligence large language models in drug target discovery. Front Pharmacol. 2025 Jul 7 https://doi.org/10.3389/fphar.2025.1597351 PMid:40697660 PMCid:PMC12279696
53. Yu E, Chu X, Zhang W, Meng X, Yang Y, Ji X, Wu C. Large Language Models in Medicine: Applications, Challenges, and Future Directions. Int J Med Sci. 2025 May 31 https://doi.org/10.7150/ijms.111780 PMid:40520893 PMCid:PMC12163604
54. Collins S, Mathews J, Robertson J. Ethical and Regulatory Challenges of Artificial Intelligence in Drug Discovery. ACS Omega. 2025 Jun 5
55. Food and Drug Administration (FDA). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products: Draft Guidance. Silver Spring (MD): FDA; 2025 May 31
56. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. 2019;25(1):44-56. https://doi.org/10.1038/s41591-018-0300-7 PMid:30617339
57. Bhatnagar R, et al. How can natural language processing help model informed drug development? A review. J Transl Med. 2022 Jun 10 https://doi.org/10.1093/jamiaopen/ooac043 PMid:35702625 PMCid:PMC9188322
58. Sachdev D, Gupta A, Sharma V. Integration of artificial intelligence in drug discovery and development: Applications, challenges and future perspectives. Indian J Pharm Pharmacol. 2025
59. Ocana A, et al. Integrating artificial intelligence in drug discovery and early development: opportunities and challenges. Pharmaceutics. 2025 Mar 13 https://doi.org/10.1186/s40364-025-00758-2 PMid:40087789 PMCid:PMC11909971
60. Wang C, et al. Drug discovery and mechanism prediction with explainable graph neural networks. Sci Rep. 2025. https://doi.org/10.1038/s41598-024-83090-3 PMid:39747341 PMCid:PMC11696803
61. Zhang Y, Liu Y, Wang J. Network pharmacology and artificial intelligence in drug discovery: Opportunities and challenges. Sci Rep. 2025 Mar 29. https://doi.org/10.5376/cmb.2024.14.0003 PMid:39329958
62. Jarallah SJ. Artificial intelligence revolution in drug discovery. Eur J Pharm Sci. 2025;150:105417
63. Kadan A, et al. Guided multi-objective generative AI to enhance structure-based drug design. Chem Sci. 2025 Jul 22 https://doi.org/10.1039/D5SC01778E/v3/response1 PMid:40463429 PMCid:PMC12127851
64. Wan Z. Applications of Artificial Intelligence in Drug Repurposing. Adv Sci (Weinh). 2025 https://doi.org/10.1002/advs.202411325 PMid:40047357 PMCid:PMC11984889
65. Lee H, Kim J-W, Lee Y. Recent advances in AI-based toxicity prediction for drug discovery. Front Chem. 2025 Jul 7 https://doi.org/10.3389/fchem.2025.1632046 PMid:40698059 PMCid:PMC12279745
66. Satheeskumar R. Enhancing drug discovery with AI: Predictive modeling of pharmacokinetics using Graph Neural Networks and ensemble learning. Intell Pharm. 2025 Apr. https://doi.org/10.1016/j.ipha.2024.11.002
67. Mehta N, Pandya P, Mehta A. Artificial Intelligence in Clinical Trial Optimization: Enhancing Patient Recruitment, Trial Design, and Monitoring. Drug Discov Today. 2025
68. Jarallah SJ. Artificial intelligence revolution in drug discovery. Eur J Pharm Sci. 2025;150:105417.
69. Vamathevan J, Clark D, Czodrowski P, et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and Future Perspectives. Front Pharmacol. 2023
70. Haslam C. How AI will reshape pharma in 2025. Drug Target Rev. 2024 Dec 19
Published
Abstract Display: 184 
PDF Downloads: 198 PDF Downloads: 38 How to Cite
Issue
Section
Copyright (c) 2025 Nishita Nagpure , Harshal Raut , Shubham Kamble , Tirupati Rasala
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.